ARENA PHARMACEUTICALS INC Form 8-K February 03, 2006

# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## Form 8-K

Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 1, 2006

# Arena Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction of incorporation)

23-2908305 (Commission File Number)

000-31161 (I.R.S. Employer Identification No.)

6166 Nancy Ridge Drive, San Diego California (Address of principal executive offices)

92121 (Zip Code)


Registrant s telephone number, including area code: (858) 453-7200

Not Applicable.

(Former name or former address, if changed since last report.)

### Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



### Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

#### Item 8.01 Other Events.

On February 2, 2006, Arena Pharmaceuticals, Inc. (the Company) announced that the underwriters have exercised an over-allotment option to purchase an additional 885,016 shares of its common stock in connection with its follow-on stock offering that priced on January 26, 2006. Including the over-allotment shares being purchased, the offering will total 10,637,524 shares at a public offering price of \$16.90 per share. After deducting the underwriting discounts and commissions and other expenses of the offering, the Company expects the proceeds of the offering to be approximately \$169.0 million.

2

## Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### ARENA PHARMACEUTICALS, INC.

Dated: February 2, 2006 By: /s/ Steven W. Spector

Steven W. Spector,

Senior Vice President, General Counsel and Secretary

3